Latest editorial
NHS could save ‘hundreds of millions a year’ after High Court slaps pharma companies down
Sam Tobin is at the High Court
Focus on equal access to assisted death rather than risks of legalisation for oppressed groups wrongheaded, MPs and campaigners say
THE NHS could save “hundreds of millions of pounds” a year after 12 clinical commissioning groups (CCGs) won a landmark legal fight to use an equally effective and significantly cheaper sight-saving drug.
Pharmaceutical giants Bayer and Novartis took the CCGs to the High Court after they decided to start treating wet age-related macular degeneration (AMD) — the leading cause of vision loss — with anti-cancer drug Avastin.
The companies — which market rival, licensed drugs Eylea and Lucentis — argued it was unlawful for the CCGs to use Avastin because it is not licensed for the treatment of wet AMD.
More from this author
All eight claimants say Labour acted unfairly by failing to close investigations or revoke their suspension or expulsion
